Holen Sie sich die Stockscreener-App
0.5486
0.25%
-0.0014
Vorhandelsmarkt:
.55
0.0014
+0.26%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MRNS?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$0.55
Offen:
$0.5475
24-Stunden-Volumen:
1.13M
Relative Volume:
0.62
Marktkapitalisierung:
$30.29M
Einnahmen:
$30.99M
Nettoeinkommen (Verlust:
$-141.41M
KGV:
-0.2086
EPS:
-2.63
Netto-Cashflow:
$-118.12M
1W Leistung:
+1.48%
1M Leistung:
+2.81%
6M Leistung:
-52.30%
1J Leistung:
-94.51%
1-Tages-Spanne:
$0.5461
$0.55
1-Wochen-Bereich:
$0.54
$0.55
52-Wochen-Spanne:
$0.2202
$10.50
Marinus Pharmaceuticals Inc Stock (MRNS) Company Profile
Firmenname
Marinus Pharmaceuticals Inc
Sektor
Branche
Telefon
484-801-4670
Adresse
5 RADNOR CORPORATE CENTER SUITE 500, RADNOR, PA
Vergleichen Sie MRNS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRNS
Marinus Pharmaceuticals Inc
|
0.5486 | 30.29M | 30.99M | -141.41M | -118.12M | -2.63 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Marinus Pharmaceuticals Inc Stock (MRNS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-23 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-08-14 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2024-04-16 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-04-15 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-01-20 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-09-30 | Eingeleitet | Truist | Buy |
| 2020-07-01 | Eingeleitet | Cowen | Outperform |
| 2020-07-01 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-09 | Eingeleitet | Craig Hallum | Buy |
| 2019-12-20 | Eingeleitet | Oppenheimer | Outperform |
| 2019-03-05 | Fortgesetzt | Jefferies | Buy |
| 2019-02-27 | Herabstufung | Mizuho | Buy → Neutral |
| 2019-02-06 | Eingeleitet | Leerink Partners | Outperform |
| 2018-07-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-03-20 | Eingeleitet | Mizuho | Buy |
| 2018-02-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-12-14 | Eingeleitet | Laidlaw | Buy |
| 2016-08-10 | Bestätigt | Jefferies | Buy |
| 2016-06-14 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2016-03-08 | Bestätigt | Stifel | Buy |
| 2015-12-17 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2015-11-17 | Eingeleitet | Jefferies | Buy |
| 2015-10-30 | Bestätigt | Oppenheimer | Outperform |
| 2015-08-05 | Bestätigt | Oppenheimer | Outperform |
Alle ansehen
Marinus Pharmaceuticals Inc Aktie (MRNS) Neueste Nachrichten
MARINUS PHARMACEUTICALS, INC. (NASDAQ: MRNS) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Marinus Pharmaceuticals, Inc. Investors of Upcoming Deadline - ACCESS Newswire
Morgan Stanley's Strategic Acquisition of Marinus Pharmaceuticals Shares - GuruFocus.com
Vanguard Group Inc Reduces Holdings in Marinus Pharmaceuticals I - GuruFocus.com
MRNS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Marinus Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Marinus Pharmaceuticals director sells shares worth $869 - MSN
UPCOMING MRNS DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Marinus Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
Marinus pharmaceuticals director sells shares for $864 - MSN
Marinus Pharmaceuticals (MRNS) Stock Price, News & Analysis - MarketBeat
Marinus pharmaceuticals director sells shares for $864 By Investing.com - Investing.com Canada
Immedica to buy Marinus Pharmaceuticals for $151m - MSN
Fragile X Syndrome Market Predicted to See Upsurge Through 2034, Highlights DelveInsight | Novartis, Neuren Pharma, Roche, Seaside Therapeutics, Inc., Marinus Pharma, Lysogene - Barchart
Fragile X Syndrome Market Predicted to See Upsurge Through 2034, - openPR
$TOCKHOLDER ALERT: The M&A Class Action Firm Encourages Shareholders of AE, MRNS, SASR, ROIC to Take Action - The Malaysian Reserve
Marinus plummets 78% as phase 3 interim analysis of ganaxolone disappoints - MSN
Marinus Pharmaceuticals (MRNS) Upgraded to Buy: Here's What You Should Know - MSN
Beryl Capital Management LLC Acquires Significant Stake in Marin - GuruFocus.com
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Marinus Pharmaceuticals, Inc.MRNS - Kilgore News Herald
Immedica Pharma AB’s Acquisition of Marinus Pharmaceuticals - Global Legal Chronicle
MARINUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Marinus Pharmaceuticals, Inc.MRNS - Business Wire
Immedica acquires Marinus in $151 million deal - The Pharma Letter
Marinus Therapeutics in Radnor Acquired by Swedish Company - MSN
Immedica Pharma to Acquire Marinus Pharmaceuticals in $151 Million Deal - MSN
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MRNS, VCSA, MHLD on Behalf of Shareholders - Marketscreener.com
Deal Watch: Regeneron Quietly Acquires UK Ophthalmology Firm Oxular - Citeline News & Insights
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger – VINC, VCSA, MRNS, MHLD - GlobeNewswire Inc.
Marinus executives in line for bonuses after acquisition deal triggers retention payouts - The Business Journals
After phase 3 setbacks, troubled Marinus inks $151M sale to Immedica Pharma - FiercePharma
$TOCKHOLDER ALERT: The M&A Class Action Firm Is Investigating the MergerVINC, VCSA, MRNS, MHLD - Stockhouse Publishing
Neutral rating reaffirmed for Marinus stock as acquisition deal closure nears - Investing.com Canada
Marinus Pharmaceuticals to be acquired by Immedica for 55c per share - Yahoo Finance
Immedica Pharma AB entered into definitive agreement to acquire Marinus Pharmaceuticals, Inc.. - Marketscreener.com
Orion and Marinus Terminate Agreement for ganaxolone in Europe - Marketscreener.com
Immedica to buy rare disease drugmaker Marinus for $151 million - Crain's Chicago Business
Immedica to acquire Marinus Pharmaceuticals for $151 million By Investing.com - Investing.com Canada
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Me - GuruFocus.com
Marinus Pharmaceuticals ends agreements with Orion Corporation By Investing.com - Investing.com Nigeria
Marinus Pharmaceuticals ends agreements with Orion Corporation - Investing.com India
Immedica Pharma AB entered into an agreement to acquire Marinus Pharmaceuticals, Inc.. - Marketscreener.com
Immedica to Acquire Marinus Pharmaceuticals in $151 Million Deal; Shares Surge 43% - GuruFocus.com
Marinus Pharma Agrees To $151 Million Acquisition By Immedica: Shares Surge Over 40% - Benzinga
Finanzdaten der Marinus Pharmaceuticals Inc-Aktie (MRNS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.82%
0.53%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):